Latest Lisdexamfetamine Stories

PHILADELPHIA, May 17, 2013 /PRNewswire/ -- Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association (APA) 166th Annual Meeting in San Francisco, May 18-22. The data being presented...

Becomes the first stimulant medication approved for maintenance treatment in patients ages 6 and above with ADHD PHILADELPHIA, May 1, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse(R) (lisdexamfetamine dimesylate) Capsules, (CII) as a maintenance treatment in children and adolescents with...

FDA, peer-reviewed research support effectiveness of Vyvanse® as an ADHD treatment MARGATE CITY, N.J., March 12, 2013 /PRNewswire/ -- MDC announces the availability of a Vyvanse coupon through its website, redeemable towards prescriptions of Vyvanse from pharmacies. The coupon can be accessed from the bottom portion of http://medicationdiscountcard.com/drug/vyvanse-coupon/ to save up to 50% on your copay. Vyvanse (lisdexamfetamine dimesylate) is an FDA-approved medication used for...

PHILADELPHIA, February 1, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that it has reached an agreement in principle to resolve the previously disclosed civil investigation into Shire's U.S. sales and marketing practices relating to ADDERALL XR(R), VYVANSE(R) and DAYTRANA(R)[1]. The investigation was led by the U.S. Attorney's Office for the Eastern District of Pennsylvania, and Shire disclosed the investigation in 2009. The agreement also...

NYON, Switzerland, December 18, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announces a positive outcome from the European Decentralised Procedure (DCP) for Elvanse(R) (to be known as Tyvense(R) in Ireland). Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.[1]...

PHILADELPHIA, Sept. 12, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the US Food and Drug Administration (FDA) has accepted the filing for review of a supplemental New Drug Application (sNDA) for Vyvanse(®) (lisdexamfetamine dimesylate) Capsules, (CII). Shire is seeking approval of Vyvanse as a maintenance treatment in children and adolescents ages 6 to 17 years with Attention-Deficit/Hyperactivity Disorder (ADHD). There are currently no...

PHILADELPHIA, May 4, 2012 /PRNewswire/ -- Shire plc [http://www.shire.com/shireplc/en/home ] (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it will present scientific data from one oral and 16 poster presentations at the American Psychiatric Association (APA) 165th Annual Meeting to be held May 5-9. The data being presented represent Shire's ongoing commitment to the clinical research of Vyvanse(R) (lisdexamfetamine dimesylate)...

PHILADELPHIA, April 26, 2012 /PRNewswire/ -- Shire plc [http://www.shire.com/shireplc/en/home ] (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse(R)(lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder. Following discussions with the US Food and Drug Administration (FDA), Shire plans to conduct additional larger...

PHILADELPHIA, Pennsylvania, March 6, 2012 /PRNewswire/ -- Vyvanse, an approved treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, will be compared with Concerta in the treatment of adolescents with ADHD As part of its continued commitment to ADHD research, Shire plc [http://www.shire.com/shireplc/en/home ] (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it is initiating two Phase 4...

PHILADELPHIA, Feb. 7, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) as a maintenance treatment for adults with ADHD. The approval is based on results from a randomized withdrawal study designed to evaluate the efficacy of Vyvanse in adults (aged 18 to 55 years) who...